During the past decade, G+C Research Group conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "G+C Research Group" #1 collaborator was "Novo Nordisk A/S" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "G+C Research Group" are "Covid19" (1 trials) and "Nonalcoholic Steatohepatitis" (1 trials). Many other conditions were trialed in "G+C Research Group" in a lesser frequency.

Most popular intervention types in "G+C Research Group" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Cilofexor (CILO)/Firsocostat (FIR)" (1 trials), "PTM CILO/FIR" (1 trials), "PTM SEMA" (1 trials), "Placebo" (1 trials) and "STRI Formula" (1 trials). Other intervention names were less common.

The vast majority of trials in "G+C Research Group" are 2 trials for "All" genders.

Currently, there are NaN active trials in "G+C Research Group". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in G+C Research Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in G+C Research Group, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".